Home › Trial NCT03405155
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
- Trial IDNCT03405155
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Enrollment26
- Start date2018-01-17
- ConditionsMelanoma (Skin)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.